Gastrointestinal cytomegalovirus disease in the immunocompromised patient

Current Gastroenterology Reports

Volumn 10, Issue 4, 2008, Pages 409-416

  Baroco, Allison L ^a   Oldfield, Edward C ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; FOSCARNET; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VALGANCICLOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BILE DUCT DISEASE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; COLONOSCOPY; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIARRHEA; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENDOSCOPIC BIOPSY; ENTERITIS; ESOPHAGITIS; EVIDENCE BASED PRACTICE; GASTROINTESTINAL INFECTION; HEMATOCHEZIA; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; LEG EDEMA; LEUKOPENIA; MORTALITY; NAUSEA; NEUTROPENIA; ORGAN TRANSPLANTATION; PANCYTOPENIA; PATIENT SELECTION; PERIPHERAL NEUROPATHY; POSTOPERATIVE CARE; RELAPSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEROLOGY; SIGMOIDOSCOPY; TREATMENT INDICATION; VIRUS HEPATITIS; AIDS RELATED COMPLEX; GASTROINTESTINAL DISEASE; IMMUNE DEFICIENCY; NEOPLASM; OPPORTUNISTIC INFECTION; VIROLOGY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; ESOPHAGITIS; GANCICLOVIR; GASTROINTESTINAL DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; OPPORTUNISTIC INFECTIONS; ORGAN TRANSPLANTATION;

EID: 52049110117     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0077-9     Document Type: Review

References (62)

1. Centers for Disease Control and Prevention: About CMV. Available at http://www.cdc.gov/cmv/facts.htm. Accessed March 2008.
2. Crumpacker CS: Cytomegalovirus. In Principles and Practice of Infectious Diseases, edn 6. Edited by Mandell GL, Bennett JR, Dolin R. Philadelphia: Churchill Livingstone; 2005:1786-1801.
3. Palella FJ, Delaney KM, Moorman AC: Declining morbidity and mortality among patients with advanced human immuno-deficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338: 853-860.
4. Kim S, Snider JJ, Gill MJ: Cytomegalovirus disease in HIV infection: twenty years of a regional population's experience. Clin Infect Dis 2006, 42: 1808-1809.
5. Yust I, Fox Z, Burke M: Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe: A EuroSIDA study, 1994-2001. Eur J Clin Microbiol Infect Dis 2004, 7: 550-559.
6. Knox TA, Spiegelman D, Skinner SC: Diarrhea and abnormalities of gastrointestinal function in a cohort of men and women with HIV infection. Am J Gastroenterol 2000, 95: 3482-3489.
7. Benson CA, Kaplan JE, Masur H, et al.: Treating opportunistic infections among HIV-infected adults and adolescents. MMWR Recomm Rep 2004, 53: 1-112.
8. Mönkemüller KE, Lazenby AJ, Lee DH, et al.: Occurrence of gastrointestinal opportunistic disorders in AIDS despite the use of highly active antiretroviral therapy. Dig Dis Sci 2005, 50: 230-234.
9. Kirk O, Reiss P, Uberti-Foppa C, et al.: Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 2002, 137: 239-250.
10. Wilcox CM, Chalasani N, Lazenby A, et al.: Cytomegalovirus colitis in acquired immunodeficiency syndrome: A clinical and endoscopic study. Gastrointest Endosc 1998, 48: 39-43.
11. Dieterich DT, Rahmin M: CytPmegalovirus colitis in AIDS: presentation in 44 patients and a review of the literature. J Acquir Immune Defic Syndr 1991, 4(Suppl 1): S29-S35.
12. DeRodriguez CV, Fuhrer J, Lake-Bakaar G: Cytomegalovirus colitis in patients with acquired immunodeficiency syndrome. J R Soc Med 1994, 87: 203-205.
13. Goodgame RW: Gastrointestinal cytomegalovirus disease. Ann Intern Med 1993, 119: 924-935.
14. Oldfield EC: Evaluation of chronic diarrhea in patients with human immunodeficiency virus infection. Rev Gastroenterol Disord 2002, 2: 176-188.
15. Kearney DJ, Steuerwald M, Koch J, et al.: A prospective study of endoscopy in HIV-associated diarrhea. Am J Gastroenterol 1999, 95: 596-602.
16. Bini EJ, Weinshel EH: Endoscopic evaluation of chronic human immunodeficiency virus-related diarrhea: Is colonos-copy superior to flexible sigmoidoscopy? Am J Gastroenterol 1998, 93: 56-60.
17. Chamberlain RS, Atkins S, Saini N, et al.: Ileal perforation caused by cytomegalovirus infection in a critically ill adult. J Clin Gastroenterol 2000, 30: 432-435.
18. Connolly GM, Forbes A, Gleason JA, et al.: Investigation of upper gastrointestinal symptoms in patients with AIDS. AIDS 1989, 3: 453-456.
19. Bonacini M, Young T, Laine L: The causes of esophageal symptoms in human immunodeficiency virus infection. Arch Intern Med 1991, 1567-1572.
20. Enns R: AIDS cholangiopathy: "an endangered disease" [editorial]. Am J Gastroenterol 2003, 98: 2111-2112.
21. Jacobson MA, Cello JP, Sande MA: Cholestasis and disseminated cytomegalovirus disease in patients with the acquired immunodeficiency syndrome. Am J Med 1988, 84: 218-224.
22. Ko WF, Cello JP, Rogers SJ, et al.: Prognostic factors for the survival of patients with AIDS cholangiopathy. Am J Gastroenterol 2003, 98: 2176-2181.
23. Mönkemüller KE, Bussian AH, Lazenby AJ, et al.: Special histologic stains are rarely beneficial for the evaluation of HIV-related gastrointestinal infections. Am J Clin Pathol 2000, 387-394.
24. Beaugerie L, Cywiner-Golenzer C, Monfort L, et al.: Definition and diagnosis of cytomegalovirus colitis in patients infected by HIV. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 14: 423-429.
25. Paya CV, Razonable RR: Cytomegalovirus infection after solid organ transplantation. In Transplant Infectious Diseases, edn 2. Edited by Bowden RA, Ljungman P, Paya CV. Philadelphia: Lippincott Williams & Wilkins; 2003:298-325.
26. Kalil AC,TLevitsky J, Lyden E, et al.: Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients. Ann Intern Med 2005, 143: 870-880.
27. Arthurs SK, Eid AJ, Pederson RA, et al.: Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation. Clin Infect Dis 2008, 46: 840-846.
28. Arthurs SK, Eid AJ, Pedersen RA, et al.: Delayed-onset primary cytomegalovirus disease after liver transplantation. Liver Transpl 2007, 13: 1703-1709.
29. Kijpittayarit-Arthurs S, Eid AJ, Kremers WK, et al.: Clinical features and outcomes of delayed-onset primary cytomegalovirus disease in cardiac transplant recipients. J Heart Lung Transplant 2007, 26: 1019-1024.
30. Limaye AP, Bakthavatsalam R, Kim HR: Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. Transplantation 2004, 78: 1390-1396.
31. Potena L, Holweg CT, Chin C, et al.: Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82: 398-405.
32. Stripolli GF, Hodson EM, Jones C, et al.: Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients. Transplantation 2006, 81: 139-145.
33. Fica A, Cervera C, Perez N, et al.: Immunohistochemically proven cytomegalovirus end-organ disease in solid organ transplant patients: clinical features and usefulness of conventional diagnostic tests. Transpl Infect Dis 2007, 9: 203-210.
34. Dummer JS: Cytomegalovirus infection after liver transplantation: clinical manifestations and strategies for prevention. Rev Infect Dis 1990, 12(Suppl 7): S767-S775.
35. Torres HA, Kontoyiannis DP, Bodey GP, et al.: Gastrointestinal cytomegalovirus disease in patients with cancer: A two decade experience in a tertiary care cancer center. Eur J Cancer 2005, 41: 2268-2279.
36. Van Burik JA, Lawatsch EJ, DeFor TE, et al.: Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2001, 7: 674-679.
37. Ljungeman P, Griffiths P, Paya C: Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34: 1094-1097.
38. Peter A, Telkes G, Varga M, et al.: Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 2004, 18: 580-584.
39. Pereyra F, Rubin R: Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004, 17: 357-371.
40. Humar A, Mazzuli T, Moussa G, et al.: Clinical utility of cytomegalovirus (CMV) serology testing in high-risk D+/R-transplant recipients. Am J Transplant 2005, 5: 1065-1070.
41. Rowshani AT, Bemelman FJ, van Leeuwen EM, et al.: Clinical and immunologic aspects of cytomegalovirus infection in solid organ transplant recipients. Transplantation 2005, 79: 381-386.
42. Koskinen PK, Nieminen MS, Mattila SP, et al.: The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 1993, 55: 547-551.
43. Abecassis MM, Koffron AJ, Kaplan B, et al.: The role of PCR in the diagnosis and management of CMV in solid organ recipients: What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 1997, 63: 275-279.
44. Geddes CC, Church CC, Collidge T, et al.: Management of cytomegalovirus infection by weekly surveillance after renal transplant: Analysis of cost, rejection and renal function. Nephrol Dial Transplant 2003, 18: 1891-1898.
45. Humar A, Paya P, Pescovitz MD, et al.: Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients. Am J Transplant 2004, 4: 644-649.
46. Gottschalk S, Rooney CM, Heslop HE: Post-transplant lymphoproliferative disorders. Annu Rev Med 2005, 56: 29-44.
47. Adani GL, Baccarani U, Lorenzin D, et al.: De novo gastro-intestinal tumours after renal transplantation: Role of CMV and EBV viruses. Clin Transplant 2006, 20: 457-460.
48. Powell RD, Warner NE, Levine RS, et al.: Cytomegalic inclusion disease and ulcerative colitis; report of a case in a young adult. Am J Med 1961, 30: 334-340.
49. Hommes DW, Sterringa G, van Deventer SJ, et al.: The pathogenicity of cytomegalovirus in inflammatory bowel disease: A systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004, 10: 245-250.
50. Cottone M, Pietrosi G, Martorana A, et al.: Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001, 96: 773-775.
51. Kambham N, Vij K, Cartwright CA, et al.: Cytomegalovirus infection in steroid refractory ulcerative colitis: A case control study. Am J Surg Pathol 2004, 28: 365-373.
52. Dimitroulia E, Spanakis N, Konstantinidou A: Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006, 12: 879-884.
53. Kandiel A, Lashner B: Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006, 101: 2857-2865.
54. Criscuoli V, Casa A, Orlando A, et al.: Severe acute colitis associated with CMV: A prevalence study. Dig Liver Dis 2004, 36: 818-820.
55. Pescovitz MD, Rabkin J, Merion RM, et al.: Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000, 44: 2811-2815.
56. Martin D, Sierra-Madero J, Walmsley S, et al.: A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002, 346: 1119-1126.
57. Len O, Gavaldà J, Aguado JM, et al.: Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients. Clin Infect Dis 2008, 46: 20-27.
58. Asberg A, Humar A, Rollag H, et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7: 2106-2113.
59. Boivin G, Goyette N, Gilbert C, et al.: Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid-organ transplant patients. Transpl Infect Dis 2005, 7: 166-170.
60. Razonable RR, Paya CV: Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts. Expert Rev Anti Infect Ther 2004, 2: 27-41.
61. Berenguer J, Mallolas J: Intravenous cidofovir for compassionate use in AIDS patients with cytomegalovirus retinitis. Spanish Cidofovir Study Group. Clin Infect Dis 2000, 30: 182-184.
62. Hodson EM, Jones CA, Strippoli GF, et al.: Immunoglobulins, vaccines, or interferon for preventing cytomegalovirus disease in solid-organ transplants. Cochrane Database Syst Rev 2007, CD 005129.